|
市場調查報告書
中型製藥企業未來展望（至2016年）
Mid Pharma Company Outlook to 2016
| 出版商 |
Datamonitor |
| 出版日期 |
2011年11月 |
商品編碼 |
229446 |
| 內容資訊 |
英文 Pages: 38 |
| 價格 |
|
|
中型製藥企業未來展望（至2016年） 是由出版商Datamonitor在2011年11月所出版的。
這份英文市場調查報告書包含Pages: 38 價格從美金3800起跳。
本報告針對全球中型製藥企業未来展望進行分析，提供未來6年業績預測、生産・開發策略預測、預估會成長的企業業績預測等內容，目錄介紹如下。
摘要整理
- 主要分析結果
- 企業比較分析概要
- 至2016年未来展望
介紹
策略考察
- 2家公司對市場成長的促進
- Gilead與Celgene對市場成長的促進
- 面對市場縮小的3家公司
中型製藥企業至2016年未来展望
- 概要
- 處方藥販售量（2004∼16年）
- 市場環境（2010∼16年）
- 企業分析
- 新發售/主力商品/專利到期分析
- 治療領域分析
- 分子種類分析
附錄
Description
Introduction
This analysis examines the outlook for companies in Datamonitor's Mid Pharma peer set. The report encompasses insight into key strategic themes across the group of companies and identifies sales trends using 6-year prescription pharmaceutical sales forecasts for all the companies covered.
Features and benefits
- Gain insight into Mid Pharma companies strategic outlook across the next 6 years
- Analyze sales forecasts by company, therapy area, lifecycle stage, and molecule type.
Highlights
- Strategic insight into the prospects for Mid Pharma companies over the next six years. Picking out key trends across the companies and comparing performance using a variety of cuts of forecast sales.
Your key questions answered
- Benchmark companies outlook against key rivals across Datamonitor's Mid Pharma peer set
- Assess how two companies in particular - Celegene and Gilead - will provide the majority of sales growth momentum within Mid Pharma through to 2016
TOC
Executive Summary
- Key findings
- Overview of the Mid Pharma peer set
- Mid Pharma prescription pharma sales performance, 2004-16
- The Mid Pharma company outlook to 2016
INTRODUCTION
- Data sourcing
- Further reading
STRATEGIC INSIGHT
- Two companies drive Mid Pharma growth
- Gilead and Celgene growth drivers
- Three companies face declines
THE MID PHARMA OUTLOOK TO 2016
- Overview of Mid Pharma to 2016
- Mid Pharma prescription pharma sales performance, 2004-16
- Mid Pharma landscape, 2010-16
- Mid Pharma company analysis
- Mid Pharma launch/core/expiry analysis
- Mid Pharma therapy area analysis
- Mid Pharma molecule type analysis
APPENDIX
- References
- Exchange rates
|
